TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science ...

TriLink BioTechnologies, a Maravai LifeSciences company and provider of life science reagents and services, has partnered ...

TriLink BioTechnologies, a Maravai LifeSciences company (MRVI), has partnered with, Avantor (AVTR) to expand availability of its innovative ...

The proposed guidance aims to provide a framework for the approval of personalised mRNA-based cancer vaccines.

The Board declared a quarterly dividend of $0.125 per share, payable on April 3, 2025 to shareholders of record on March 12, 2025.

KBR announced today its participation in upcoming February 2025 investor conferences. TD Cowen 46th Annual Aerospace and ...

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report).